2. What is dengue?
• Dengue (break-bone fever) is a viral infection that spreads from
mosquitoes to people.
• 4 serotypes involved (DENV) 1, 2, 3, and 4.
• It is more common in tropical and subtropical climates.
• dengue is now endemic in over 100 countries (40% world
population)
• 390 million dengue virus
infections per year of which 96
million manifest clinically and
21,000 deaths.
3. Dengvaxia
• First vaccine to be licensed
• DENGVAXIA® (Tetravalent recombinant)
• Introduced by Sanofi Pasteur, A French
multinational pharmaceutical and
healthcare company
• Indication: for the prevention of dengue
disease caused by dengue virus serotypes 1, 2, 3 and
4,approved for use in individuals 6-16 years of age with
laboratory-confirmed previous dengue infection and living in
endemic areas.
4.
5. • Dosage and administration : Subcutaneous vaccine,
given in three doses (0.5 mL each) 6 months apart (at
month 0, 6, and 12).
• Preparation: The package contains a vial of lyophilized
vaccine antigen and a vial of saline diluent (0.4% NaCl).
after reconstitution vaccine should be administered within
30mins or stored at 2C to 8C .
Contraindicated for immunocompromised individuals
• Adverse reactions: Headache, injection site pain, malaise
,myalgia
6.
7. REFERANCES
Dengvaxia- Full prescription information given by Sanofi
Pasteur Inc,2023
Guideline on management of Dengue Fever and dengue
hemorrhagic fever in children and adolescents-May 2023
WHO- Official website
Wong JM, Adams LE, Durbin AP, et al. Dengue: A Growing
Problem With New Interventions. Pediatrics.
2022;149(6):e2021055522
